Barclays’s Astera Labs ALAB Stock Holding History

Barclays’s Portfolio ALAB Stock Details ALAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-100	Closed	-$5.24K	–	5525
2024 Q3	$5.24K	Buy	+100	New	+$4.69K	﹤0.01%	5027

Other funds holding ALAB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Atreides Management Boston, Massachusetts $5B AUM 78.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return

Barclays's ALAB Position: Q1 2026 in Review

Barclays increased its Astera Labs (ALAB) stake by 35% in Q1 2026, buying an estimated $57.6M and bringing the position to 1,554,180 shares worth $170M. The position accounts for 0.04% of the portfolio, ranked #343.

Barclays first reported a position in ALAB in Q1 2024 and has held it in 9 quarters since. The position peaked at $395M in Q3 2025. 704 funds tracked by Wall St. Rank hold ALAB as of Q1 2026.

Barclays held 1,554,180 shares of Astera Labs worth $170M as of Q1 2026.
Barclays bought 404,100 Astera Labs shares in Q1 2026, an estimated $57.6M.
Astera Labs made up 0.04% of Barclays's portfolio in Q1 2026, its #343 holding.
Barclays first reported a position in Astera Labs in Q1 2024 and has held it in 9 quarters since.
Barclays's Astera Labs position peaked at $395M in Q3 2025.
704 funds tracked by Wall St. Rank held Astera Labs as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.